Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab

Kotaro Ogawa, Takayuki Matsumoto, Motohiro Esaki, takehiro torisu, Mitsuo Iida

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and aims: The effects of maintenance infliximab for Crohn's disease vary widely among patients. The aim of this study was to examine the cytokine profiles and to identify possible markers predictive of therapeutic effect of maintenance infliximab. Methods: Cytokine profiles of 35 Crohn's disease patients under maintenance infliximab therapy were analyzed prospectively. Blood samples were obtained prior to, and 2 and 6. weeks after infliximab infusion. Circulating cytokine values of interleukin (IL)-23, IL-17A, IL-12, IL-6, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were compared according to the disease activity and therapeutic efficacy. Patients were classified into either the active or quiescent phase according to their disease activity at baseline. Patients were also divided into a sustained response group and non-sustained response group according to therapeutic efficacy of infliximab determined 2 and 6. weeks after infliximab infusion. Results: At baseline, serum levels of IL-23 (p < 0.05), IL-17A (p < 0.01), IFN-γ (p < 0.05), and IL-6 (p < 0.01) were significantly higher in active Crohn's disease than in quiescent disease. These cytokine levels remained unchanged during the follow-up period. When serum cytokine levels were compared between groups classified by therapeutic efficacy of infliximab, patients in the non-sustained response group had a significantly higher level of serum IL-17A than those in the sustained response group (p < 0.05). There were also trends toward higher serum IL-23 and IL-12 in the former than in the latter. Conclusion: Higher levels of IL-17A, IL-23, and IL-12 at baseline may be predictive markers for poor therapeutic response to maintenance infliximab therapy.

Original languageEnglish
Pages (from-to)529-535
Number of pages7
JournalJournal of Crohn's and Colitis
Volume6
Issue number5
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Crohn Disease
Interleukin-17
Cytokines
Interleukin-23
Interleukin-12
Maintenance
Therapeutics
Serum
Interleukin-6
Infliximab
Therapeutic Uses
Interferon-gamma
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab. / Ogawa, Kotaro; Matsumoto, Takayuki; Esaki, Motohiro; torisu, takehiro; Iida, Mitsuo.

In: Journal of Crohn's and Colitis, Vol. 6, No. 5, 01.06.2012, p. 529-535.

Research output: Contribution to journalArticle

Ogawa, Kotaro ; Matsumoto, Takayuki ; Esaki, Motohiro ; torisu, takehiro ; Iida, Mitsuo. / Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab. In: Journal of Crohn's and Colitis. 2012 ; Vol. 6, No. 5. pp. 529-535.
@article{309c9ed943b2477d84667353a2a1e547,
title = "Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab",
abstract = "Background and aims: The effects of maintenance infliximab for Crohn's disease vary widely among patients. The aim of this study was to examine the cytokine profiles and to identify possible markers predictive of therapeutic effect of maintenance infliximab. Methods: Cytokine profiles of 35 Crohn's disease patients under maintenance infliximab therapy were analyzed prospectively. Blood samples were obtained prior to, and 2 and 6. weeks after infliximab infusion. Circulating cytokine values of interleukin (IL)-23, IL-17A, IL-12, IL-6, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were compared according to the disease activity and therapeutic efficacy. Patients were classified into either the active or quiescent phase according to their disease activity at baseline. Patients were also divided into a sustained response group and non-sustained response group according to therapeutic efficacy of infliximab determined 2 and 6. weeks after infliximab infusion. Results: At baseline, serum levels of IL-23 (p < 0.05), IL-17A (p < 0.01), IFN-γ (p < 0.05), and IL-6 (p < 0.01) were significantly higher in active Crohn's disease than in quiescent disease. These cytokine levels remained unchanged during the follow-up period. When serum cytokine levels were compared between groups classified by therapeutic efficacy of infliximab, patients in the non-sustained response group had a significantly higher level of serum IL-17A than those in the sustained response group (p < 0.05). There were also trends toward higher serum IL-23 and IL-12 in the former than in the latter. Conclusion: Higher levels of IL-17A, IL-23, and IL-12 at baseline may be predictive markers for poor therapeutic response to maintenance infliximab therapy.",
author = "Kotaro Ogawa and Takayuki Matsumoto and Motohiro Esaki and takehiro torisu and Mitsuo Iida",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.crohns.2011.10.010",
language = "English",
volume = "6",
pages = "529--535",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab

AU - Ogawa, Kotaro

AU - Matsumoto, Takayuki

AU - Esaki, Motohiro

AU - torisu, takehiro

AU - Iida, Mitsuo

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background and aims: The effects of maintenance infliximab for Crohn's disease vary widely among patients. The aim of this study was to examine the cytokine profiles and to identify possible markers predictive of therapeutic effect of maintenance infliximab. Methods: Cytokine profiles of 35 Crohn's disease patients under maintenance infliximab therapy were analyzed prospectively. Blood samples were obtained prior to, and 2 and 6. weeks after infliximab infusion. Circulating cytokine values of interleukin (IL)-23, IL-17A, IL-12, IL-6, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were compared according to the disease activity and therapeutic efficacy. Patients were classified into either the active or quiescent phase according to their disease activity at baseline. Patients were also divided into a sustained response group and non-sustained response group according to therapeutic efficacy of infliximab determined 2 and 6. weeks after infliximab infusion. Results: At baseline, serum levels of IL-23 (p < 0.05), IL-17A (p < 0.01), IFN-γ (p < 0.05), and IL-6 (p < 0.01) were significantly higher in active Crohn's disease than in quiescent disease. These cytokine levels remained unchanged during the follow-up period. When serum cytokine levels were compared between groups classified by therapeutic efficacy of infliximab, patients in the non-sustained response group had a significantly higher level of serum IL-17A than those in the sustained response group (p < 0.05). There were also trends toward higher serum IL-23 and IL-12 in the former than in the latter. Conclusion: Higher levels of IL-17A, IL-23, and IL-12 at baseline may be predictive markers for poor therapeutic response to maintenance infliximab therapy.

AB - Background and aims: The effects of maintenance infliximab for Crohn's disease vary widely among patients. The aim of this study was to examine the cytokine profiles and to identify possible markers predictive of therapeutic effect of maintenance infliximab. Methods: Cytokine profiles of 35 Crohn's disease patients under maintenance infliximab therapy were analyzed prospectively. Blood samples were obtained prior to, and 2 and 6. weeks after infliximab infusion. Circulating cytokine values of interleukin (IL)-23, IL-17A, IL-12, IL-6, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were compared according to the disease activity and therapeutic efficacy. Patients were classified into either the active or quiescent phase according to their disease activity at baseline. Patients were also divided into a sustained response group and non-sustained response group according to therapeutic efficacy of infliximab determined 2 and 6. weeks after infliximab infusion. Results: At baseline, serum levels of IL-23 (p < 0.05), IL-17A (p < 0.01), IFN-γ (p < 0.05), and IL-6 (p < 0.01) were significantly higher in active Crohn's disease than in quiescent disease. These cytokine levels remained unchanged during the follow-up period. When serum cytokine levels were compared between groups classified by therapeutic efficacy of infliximab, patients in the non-sustained response group had a significantly higher level of serum IL-17A than those in the sustained response group (p < 0.05). There were also trends toward higher serum IL-23 and IL-12 in the former than in the latter. Conclusion: Higher levels of IL-17A, IL-23, and IL-12 at baseline may be predictive markers for poor therapeutic response to maintenance infliximab therapy.

UR - http://www.scopus.com/inward/record.url?scp=84860835015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860835015&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2011.10.010

DO - 10.1016/j.crohns.2011.10.010

M3 - Article

C2 - 22398057

AN - SCOPUS:84860835015

VL - 6

SP - 529

EP - 535

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 5

ER -